Skip to main content
Evidence Snapshot

Aldehyde oxidase

CHEMBL3257 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:11:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3257
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Aldehyde oxidase as ChEMBL target CHEMBL3257, mapped to UniProt Q06278. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Aldehyde oxidase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3257
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q06278
Aldehyde oxidase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Aldehyde oxidase matters

As of 2026-09-13

Aldehyde oxidase is reviewed as Aldehyde oxidase (UniProt Q06278); the current evidence base includes 20 approved drugs, 215 compounds, and 140 assays, with lead potency reaching pChEMBL 9.1.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 20 approved drugs, 215 compounds, and 140 assays for this target. The dominant activity type is KI. CHEMBL81 is the current potency anchor at pChEMBL 9.1.

Use CHEMBL81 as the tractability anchor when discussing potency (pChEMBL 9.1).

Activity source · ChEMBL 36 via Core Engine
20 approved pChEMBL 9.1
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Aldehyde oxidase matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q06278, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

215
Total Compounds
140
Total Assays
20
Approved Drugs
IC50: 27.0, KI: 30.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL81
 9.1 Ki Approved
No preferred name
CHEMBL81
 8.5 IC50 Approved
No preferred name
CHEMBL44
 8.3 IC50 Clinical
No preferred name
CHEMBL135
 8.3 IC50 Approved
No preferred name
CHEMBL691
 8.3 IC50 Approved

Approved Drugs

Structure Compound First Approval
RALOXIFENE
CHEMBL81
 1997
ETHINYL ESTRADIOL
CHEMBL691
 1982
MENADIONE
CHEMBL590
 1982
ESTRADIOL
CHEMBL135
 1975
DIETHYLSTILBESTROL
CHEMBL411
 1973
PERPHENAZINE
CHEMBL567
 1957
CHLORPROMAZINE
CHEMBL71
 1957
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T16:11:55Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3257